Advertisement
U.S. markets closed
Advertisement

NovaBay Pharmaceuticals, Inc. (NBY)

NYSE American - NYSE American Delayed Price. Currency in USD
Visitors trend2W10W9M
0.2894-0.0075 (-2.53%)
At close: 03:59PM EST
0.2872 -0.00 (-0.76%)
After hours: 07:51PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Hammer

Hammer

Performance Outlook
Previous Close0.2969
Open0.2885
Bid0.2881 x 1300
Ask0.2871 x 1000
Day's Range0.2822 - 0.2910
52 Week Range0.2800 - 2.6600
Volume111,795
Avg. Volume1,119,026
Market Cap1.89M
Beta (5Y Monthly)2.69
PE Ratio (TTM)N/A
EPS (TTM)-7.0500
Earnings DateNov 09, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.65
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NBY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NovaBay Pharmaceuticals, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • Business Wire

    NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes

    EMERYVILLE, Calif., December 06, 2023--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes. A free webinar is being held Thursday, December 7, 2023 from 5:30-6:30 pm Pacific time, and eyecare professionals can register here. In September 2023 NovaBay commercially launched its prescription amniotic membrane product Avenova® Allograft, which is intended for use as a prote

  • Insider Monkey

    NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call Transcript

    NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Welcome to the NovaBay Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to Ms. Jody Cain. Please go ahead, ma’am. Jody Cain: This […]

  • Business Wire

    NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results

    EMERYVILLE, Calif., November 09, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2023 and provides a business update.